The global intravenous infusion pump market size was estimated at USD 5.3 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.3% from 2023 to 2030. Intravenous infusion pumps are used to administer medications, hormones, and nutritional fluids into the circulatory system through veins, in controlled amounts. Intravenous infusion pumps are in extensive use in clinical settings such as hospitals, nursing homes, and homes. The pump is operated by a trained operator by programming the rate and duration of fluid delivery using built-in software. Intravenous infusion pumps can deliver nutrients, hormones, antibiotics, chemotherapy drugs, and pain relievers.
The advent of COVID-19 resulted in burdening of healthcare infrastructure globally as the majority of elective healthcare treatments were postponed. However, the demand for intravenous infusion pumps such as insulin infusion pumps andvolumetric infusion pumps witnessed an increase. The majority of patients suffering from chronic diseases were treated remotely from home to prevent the risk of disease transmission and to unburden the healthcare facilities.
Infusion pumps offer various advantages over manual administration of medicated fluids like the ability to deliver fluids in very small volumes. Furthermore, it also offers the ability to deliver fluids at precise programmed rates or automated intervals. Therefore, these remain highly adopted by healthcare systems. However, product recalls and infusion pumps malfunctions such as software defects and user interface issues are the major growth restraining factors for the market
The key factors driving the growth of the market include increased incidences of chronic diseases, rapid escalation seen in the geriatric population, rising surge for ambulatory infusion pumps, and the burgeoning number of people undergoing surgical procedures. Intravenous infusion pumps are mainly used to administer critical fluids that include high-risk medication. Most of the infusion pumps are equipped with safety features and in-built alarms for operator alerts intended to activate in the event of a problem. Many conditions such as immune deficiencies, cancer, and congestive heart failure cannot be treated with oral medications and require infusion therapy.
While administering medication, vitamins, minerals, amino acids, and varied essential micronutrients can also be added to the infusion for collateral nutrition, which proves yet another benefit of intravenous infusion pumps. Smart pumps are intravenous pumps that are technologically advanced features such as automation, drug libraries, and various operator and patient safety features for accurate, precise, and controlled delivery. Such delivery of fluids into the patient’s body is especially beneficial in the treatment of chemotherapy. Hence, smart pumps continue to gain tremendous traction in the medical sector.
On the basis of disease indication, chemotherapy is projected to be the fastest-growing segment over the forecast period. According to the WHO, 19.3 million new cases of cancer and almost 10.0 million cancer deaths were reported globally in 2020. However, effective cancer treatments are on the rise which has led to an increase in the number of cancer survivors.
Moreover, a report by WHO states that the percentage of the world’s population over 60 years will double from 12% to 22% between 2015- 2050 indicating a rise in the geriatric population. This combined with the high risk of chronic and long-term health conditions, promises a market for infusion pumps that will play an important role in infusion therapies for chronically ill patients.
The demand for intravenous infusion pumps increased considerably after the onset of Covid-19, Patient monitoring devices manufacturer, Smiths Medical stated that demand for items such as ventilators, airway management products, patient monitors, and infusion pumps increased substantially. The company’s revenue from infusion systems increased by 4% in 2020, driven by COVID-19-related demand. ICU Medical also reported that the demand for its infusion systems increased due to high demand from existing customers and government stockpile orders.
The demand for intravenous pumps in the post-pandemic era is also expected to witness significant growth as the prevalence of diseases like diabetes, cancer, and heart ailments are expected to rise due to rapid lifestyle changes. These factors will boost the demand for intravenous infusion pumps throughout the forecast period.
Volumetric infusion pumps held the largest market share of 16.8% in 2022. Based on product, the intravenous infusion pump market is segmented into volumetric infusion pumps, syringe infusion pumps, insulin infusion pumps, enteral infusion pumps, ambulatory infusion pumps, patient-controlled analgesia infusion pumps, and implantable infusion pumps. Volumetric infusion pumps held the largest market share in 2022 as these pumps are capable of delivering continuous and very specific amounts of fluids at very slow to very fast rates.
The ambulatory infusion pumps, which are used to deliver liquid nutrients and medications to a patientin both emergencies and chronic conditions, contributed a significant market share in 2022. These pumps are widely favored for the delivery of nutrients and medications. The availability of other pumps like patient-controlled analgesia (PCA) pumps, insulin pumps, and smart pumps will contribute to the supplementary growth of this segment. The rising demand for enteral and syringe pumps is contributing to the burgeoning preference for the intravenous infusion pump which will also lead to segment growth.
Lately, smart pumps with controlled IV medication and error-prevention software are widely used as these pumps are equipped with advanced features like drug libraries, which help in storing the amount of medicated fluid given to the patient, and its barcode technology, which helps in the verification of a patient’s identity and helps prevent drug administration errors.
On the other hand, insulin infusion pumps are anticipated to register the highest CAGR over the forecast period. This is because the global burden of diabetes and related complications has surged in the last decade mainly due to changing lifestyles and urbanization. This pump segment is expected to flourish in the latter future as it has a low incidence of infections and a low incidence of delivery system failure during treatment.
The pediatrics /neonatology segment held the largest market share of 26.5% in 2022. Based on disease indication, the market has been segmented into chemotherapy diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, hematology, and others. Pediatrics/neonatology held the largest market share in 2022 because the treatment for pediatrics has advanced considerably and with the rising number of births globally, the demand for effective pediatric care has also surged. This indicates the segment which uses intravenous infusion pumps predominantly for their medical procedures, which requires the delivery of fluids at a customizable and precise programmed rate.
Conversely, the hematology segment is estimated to be growing significantly over the forecast period. With the rising incidences of surgeries and blood cancer (hemophilia), the demand for intravenous infusion pumps has seen a surge in hematology. It is used for treatments like blood transfusion, which is expected to increase in the coming years.
Intravenous pumps are used for hematology as it is the only way that blood can be transfused into a patient’s body in a precise, compact, and continuous manner. Moreover, it can regulate manual control or in an automated manner, avoiding the risk of failure during the treatment.
North America dominated the Intravenous infusion pump market in 2022 with a share of 49.6% and this trend is expected to continue throughout the forecast period. The increasing Incidence of chronic diseases, an increasing number of surgical procedures performed, well-developed & increasing R&D, and escalating adoption of advanced technology in infusion pumps contributed to the growth the of intravenous pumps industry in this region.
The U.S. held the largest market share of the North America intravenous infusion market due to high disease prevalence, high medical R&D expenditure, and a robust healthcare system. The prevalence of diabetes in the U.S. is also quite significant, which can be attributed to their lifestyle and stressed work environment. According to the CDC, 34.2 million Americans were diagnosed with diabetes in 2018 and the number is expected to elevate in the future.
The Asia Pacific market is expected to witness a significant CAGR of 8.8% over the forecast period. Asian countries are population dense with an elevated burden of chronic diseases like diabetes, cardiovascular illnesses, and cancer. These countries are also popular for their low cost of treatment and surgeries, thus being a preferred market for medical tourism. Asian countries like China, Japan and India are emerging economies with well-developed healthcare infrastructure and facilities. Attributes like high disease burden, significant government reforms, adoption of new technology, and low cost of treatments are paving way for the intravenous infusion industry.
The market players are strategically utilizing drivers like a shift in technology, automation, and standardized dosing, and the extensive adoption of advanced healthcare technology for improved healthcare services. Moreover, major players often opt for geographical expansion to retain market share; and adopt strategies such as mergers, acquisitions, and new product launches to widen their product portfolio.
One of the key factors driving competitiveness among market players is theshift in technology, automation, and standardized dosing, and the extensive adoption of advanced healthcare technology for improved healthcare services. Moreover, major players often opt for geographical expansion to retain market share; and adopt strategies such as mergers, acquisitions, and new product launches to widen their product portfolio.
For instance, In January 2020, Medtronic announced the launch of software Efficio to efficiently manage targeted drug delivery in SynchroMed II. Also in May 2018, Baxter International launched SpectrumIQ, an infusion pump technology with integrated EMR (Electronic Medical Records), and DeviceVue, an asset tracking software to improve the efficiency of drug delivery. Some prominent players in the global intravenous infusion pumps market include:
B. Braun Melsungen AG
Micrel Medical Devices SA
Boston Scientific Corporation
F. Hoffmann-La Roche Ltd.
Tandem Diabetes Care, Inc.
Market size value in 2023
USD 5.7 billion
Revenue forecast in 2030
USD 9.9 billion
CAGR of 8.3% from 2023 to 2030
Base year for estimation
Actual estimates/Historical data
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Product, disease indication, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Netherlands; Belgium; Switzerland; Russia; Sweden; China; India; Japan; Australia; South Korea; Malaysia; Singapore; Philippines; Thailand; New Zealand; Mexico; Brazil; Argentina; Colombia; Chile; South Africa; Saudi Arabia; UAE; Israel; Egypt
Key companies profiled
Baxter International; B. Braun Melsungen AG; Medtronic; Micrel Medical Devices SA; Boston Scientific Corporation; CareFusion Corporation; Fresenius Kabi; Smiths Medical; F. Hoffmann-La Roche Ltd.; Tandem Diabetes Care, Inc.; Terumo Corporation; Mindray; Moog Inc.; IRadimed Corporation
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global intravenous infusion pump market report based on product, disease indication, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Volumetric Infusion Pumps
Insulin Infusion Pumps
Syringe Infusion Pumps
Enteral Infusion Pumps
Ambulatory Infusion Pumps
Patient Controlled Analgesia (PCA)
Implantable Infusion Pumps
Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global intravenous infusion pump market size was estimated at USD 5.3 billion in 2022 and is expected to reach USD 5.7 billion in 2023.
b. The global intravenous infusion pump market is expected to grow at a compound annual growth rate of 8.3% from 2023 to 2030 to reach USD 9.9 billion by 2030.
b. North America dominated the intravenous infusion pumps market with a share of 49.6% in 2022. This is attributable to the increasing number of surgical procedures performed, well-developed & increasing R&D, and escalating adoption of advanced technology in infusion pumps.
b. Some key players operating in the intravenous infusion pump market include Baxter International, B. Braun Melsungen AG; Medtronic; Micrel Medical Devices SA; Boston Scientific Corporation; CareFusion Corporation; Fresenius Kabi; and Smiths Medical.
b. Key factors that are driving the intravenous infusion pump market growth include increased incidences of chronic diseases, rapid flourishing seen in the geriatric population, rising surges for ambulatory infusion pumps, and the burgeoning number of people undergoing surgical procedures.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."